Methylphenidate hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
You are here : Home > Formulary Search > Methylphenidate hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Status 1
- Modified release tablets
Prescribe by brand. Xaggitin XL, Xenidate XL, Affenid XL and Delomsart are the locally agreed brands.
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
Status 2
- Immediate release tablets
Prescribe immediate release tablets generically.
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
Documentation
PAD Profile
Other Indications
Below are listed other indications that Methylphenidate hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs.
Committee Recommendations (3)
MODIFIED RELEASE TABLETS (18, 27, 36 and 54mg):
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the recommendation to prescribe the branded generic Methylphenidate modified release preparations (18, 27, 36 and 54mg) with the lowest acquisition cost.
Such products have an AMBER traffic light status and are the preferred alternatives to Concerta®.
- See the "Branded generic methylphenidate letters" for information for patients and clinicians
N.B. This guidance does not apply to other strengths of modified release methylphenidate as these have different release characteristics
Shared Care arrangements for children and adolescents with ADHD are in place with Surrey and Borders Partnership NHS Foundation Trust.
Guildford & Waverley, North West Surrey and Surrey Downs have agreed a Locally Commissioned Service (LCS) for practices entering into the shared care agreement with Surrey & Borders Partnership. The LCS supports the provision of an annual physical medication review by the GP (with an annual review by the specialist so that the patient continues to receive a 6-monthly review in accordance with the product license)
See below for a copy of the Shared care with LCS agreement
There is also a non-LCS shared care agreement that is available for all non-LCS participating practices (see shared care agreement below)
Information on management of ADHD medication stock shortages
There are currently supply disruptions affecting various medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD).
A national patient safety alert has been issued and we have been liaising with colleagues both regionally and nationally about the ongoing situation. We have been advised that centrally they are looking at publishing further guidance but until this is published we have been working with colleagues from Surrey & Borders Partnership NHS Trust and the Local Pharmaceutical Committee to produce the pack below which provides useful information and clinical recommendations about how to manage these shortages.